Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1515-1517

  Spraggs, C F ^a   Parham, L R ^b   Song, K ^c   Briley, L P ^b   Johnson, T ^a   Russo, M ^c   Tada, H ^c   du Bois, A ^d   Xu, C F ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PAREXEL INTERNATIONAL   (United States)

^c GLAXOSMITHKLINE   (United States)

^d KLINIKEN ESSEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; DNA; GERMLINE DNA; LAPATINIB; PACLITAXEL; PAZOPANIB; SUNITINIB; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; INDOLE DERIVATIVE; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SULFONAMIDE;

ARTICLE; BIM GENE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DELETION POLYMORPHISM; DNA POLYMORPHISM; ENZYME INHIBITION; GENE DELETION; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOTE; HUMAN; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SAMPLE SIZE; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; NEOPLASMS; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; APOPTOSIS REGULATORY PROTEINS; GENE DELETION; HUMANS; INDOLES; MEMBRANE PROTEINS; NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; PYRROLES; QUINAZOLINES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84946736239     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv211     Document Type: Letter

References (5)

1. Ng KP, Hillmer AM, Chuah CTH et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012; 18: 521-528.
2. Faber AC, Corcoran RB, Ebi H et al. BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors. Cancer Disc 2011; 1: 352-365.
3. Ong ST, Chuah CTH, Ko TK et al. Reply to Chen et al. Nat Med 2014; 20:1090-1091.
4. Chen X, Liu H, Xing H et al. The BIM deletion polymorphism cannot account for intrinsic tyrosine kinase inhibitor resistance of Chinese individuals with chronic myeloid leukemia. Nat Med 2014; 20: 1090.
5. Shao Y-Y, Chang Y-L, Huang C-Y, Hsu C-H, Cheng A-L. The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorefenib in patients with advanced hepatocellular carcinoma. Oncology 2013; 85:312-316.